Skip to main content

Market Overview

Sanofi/Regneron's Dupixent Application For Asthma In Children Accepted For FDA Review


The FDA has accepted for review the supplemental marketing application seeking approval for Dupixent (dupilumab). It is an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma, jointly developed by Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) under a global collaboration agreement.

  • The target action date is October 21.
  • EU regulatory submission of Dupixent for children aged 6 to 11 years with asthma is up next.
  • It is currently approved as an add-on treatment for patients with uncontrolled moderate-to-severe asthma aged 12 and older with elevated eosinophils or oral corticosteroid-dependent asthma.
  • Dupixent is a fully human monoclonal antibody that inhibits the interleukin-4 (IL-4) signaling and interleukin-13 (IL-13) pathways that drivers of the type 2 inflammation that plays a major role in asthma, chronic rhinosinusitis with nasal polyposis, atopic dermatitis, and eosinophilic esophagitis.
  • Price Action: REGN shares closed 1.8% lower at $446.73, and SNY shares closed 1% lower at $45.46 on Wednesday.

Related Articles (REGN + SNY)

View Comments and Join the Discussion!

Posted-In: asthmaBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at